Novel Agent Combos Beat Single Agents in Melanoma
Vienna—A series of trials presented at the 2015 European Cancer Congress (ECC) confirm and expand on the evidence that advanced melanoma is best treated by combining recently approved therapies, whether these are oral agents targeted at driver mutations or checkpoint inhibitors.
In BRAF-mutant disease, an overall survival (OS) previously reported in an interim analysis was confirmed in the final analysis, providing what was called as a new standard of care. In other data, updated studies provided support for the recent approval of the checkpoint inhibitors nivolumab and ipilimumab in combination (see related story, page 7)…
